Benchmarking biomarker‐based criteria for Alzheimer's disease: Data from the Swedish Dementia Registry, SveDem
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Introduction: New research guidelines for the diagnosis of Alzheimer's disease (AD) include biomarker evidence of amyloid‐β (Aβ) and tau pathology. The aim of this study was to investigate what proportion of AD patients diagnosed in clinical routine in Sweden that had an AD‐indicative cerebrospinal fluid (CSF) biomarker profile. Methods: By cross‐referencing a laboratory database with the Swedish Dementia Registry (SveDem), 2357 patients with data on CSF Aβ and tau biomarkers and a clinical diagnosis of AD with dementia were acquired. Results: Altogether, 77.2% had pathologic Aβ 42 and total tau or phosphorylated tau in CSF. These results were stable across age groups. Female sex and low mini‐mental state examination score increased the likelihood of pathologic biomarkers. Discussion: About a quarter of clinically diagnosed AD patients did not have an AD‐indicative CSF biomarker profile. This discrepancy may partly reflect incorrect (false positive) clinical diagnosis or a lack in sensitivity of the biomarker assays.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevalence of Dementia in the United States: The Aging, Demographics, and Memory Study
Plassman, B. L., Langa, K. M., Fisher, G. G., Heeringa, S. G., Weir, D. R., Ofstedal, M. B., Burke, J. R., Hurd, M. D., Potter, G. G., Rodgers, W. L., et al. (2007) · Neuroepidemiology · doi:10.1159/000109998 · Cited by 1,932 · cited 1×
“Previous studies on sex differences in the risk for AD have given mixed results, with some showing increased risk for females and others showing no sex differences [38].”
ResultHansson, O., Zetterberg, H., Buchhave, P., Londos, E., Blennow, K., & Minthon, L. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70355-6 · Cited by 1,700 · cited 1×
“These were the optimal cut points to differentiate AD from other disorders and cognitively normal controls in an earlier study from our group [21].”
BackgroundSelf-citationKnopman, D. S., DeKosky, S. T., Cummings, J. L., Chui, H., Corey–Bloom, J., Relkin, N., Small, G. W., Miller, B., & Stevens, J. C. (2001) · Neurology · doi:10.1212/wnl.56.9.1143 · Cited by 1,410
CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment
Mattsson, N. (2009) · JAMA · doi:10.1001/jama.2009.1064 · Cited by 1,176
Self-citationBeach, T. G., Monsell, S. E., Phillips, L. E., & Kukull, W. (2012) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31824b211b · Cited by 1,103 · cited 1×
“8%, depending on the clinical and neuropathologic criteria used [24].”
BackgroundTapiola, T., Alafuzoff, I., Herukka, S.-K., Parkkinen, L., Hartikainen, P., Soininen, H., & Pirttilä, T. (2009) · Archives of Neurology · doi:10.1001/archneurol.2008.596 · Cited by 896 · cited 1×
“One study found that female sex was associated with elevated CSF T-tau levels in patients with various dementias and other neurologic diseases [29].”
BackgroundBlennow, K., Wallin, A., Ågren, H., Spenger, C., Siegfried, J., & Vanmechelen, E. (1995) · Molecular and Chemical Neuropathology · doi:10.1007/bf02815140 · Cited by 789
Self-citationCampion, D., Dumanchin, C., Hannequin, D., Dubois, B., Belliard, S., Puel, M., Thomas-Anterion, C., Michon, A., Martin, C., Charbonnier, F., et al. (1999) · The American Journal of Human Genetics · doi:10.1086/302553 · Cited by 785 · cited 1×
“It is not known whether the EOAD patients in the study have sporadic or familial AD, but among EOAD, autosomal dominant transmission is only apparent in around 10% of the cases [12].”
BackgroundAndreasen, N., Hesse, C., Davidsson, P., Minthon, L., Wallin, A., Winblad, B., Vanderstichele, H., Vanmechelen, E., & Blennow, K. (1999) · Archives of Neurology · doi:10.1001/archneur.56.6.673 · Cited by 660
Self-citationPalmqvist, S., Zetterberg, H., Blennow, K., Vestberg, S., Andreasson, U., Brooks, D. J., Owenius, R., Hägerström, D., Wollmer, P., Minthon, L., et al. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.1358 · Cited by 368 · cited 2×
“In addition, the concordance between CSF Ab42 measurements and amyloid PET is very high, also with CSF analyses performed in clinical routine, supporting the accuracy of this biomarker to identify brain amyloid deposition [20,31].”
BackgroundMethodSelf-citation
Cited by
Chételat, G., Arbizu, J., Barthel, H., Garibotto, V., Law, I., Morbelli, S., van de Giessen, E., Agosta, F., Barkhof, F., Brooks, D. J., et al. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30314-8 · Cited by 526
Self-citationHerukka, S.-K., Simonsen, A. H., Andreasen, N., Baldeiras, I., Bjerke, M., Blennow, K., Engelborghs, S., Frisoni, G. B., Gabryelewicz, T., Galluzzi, S., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.09.009 · Cited by 141
“Analytical variation (often around 10%) in the biomarker measurements may result in a fairly significant gray zone within which it is impossible to tell whether the individual patient is positive or negative for a certain biomarker [28].”
Self-citationRecommendations for CSF AD biomarkers in the diagnostic evaluation of dementia
Simonsen, A. H., Herukka, S.-K., Andreasen, N., Baldeiras, I., Bjerke, M., Blennow, K., Engelborghs, S., Frisoni, G. B., Gabryelewicz, T., Galluzzi, S., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.09.008 · Cited by 138
Self-citationKojima, Y., Kasai, T., Noto, Y.-I., Ohmichi, T., Tatebe, H., Kitaoji, T., Tsuji, Y., Kitani-Morii, F., Shinomoto, M., Allsop, D., et al. (2021) · PLOS ONE · doi:10.1371/journal.pone.0260323 · Cited by 28
Metadata
- Authors
- Rosén, C., Farahmand, B., Skillbäck, T., Nägga, K., Mattsson, N., Kilander, L., Religa, D., Wimo, A., Blennow, K., Winblad, B., Zetterberg, H., & Eriksdotter, M.
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2015-06-13
- Volume
- 11
- Issue
- 12
- Pages
- 1470-1479
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- OpenAlex
- W1891261562
- Cited by
- 20
- References
- 12
- FWCI
- 1.69
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Benchmarking biomarker‐based criteria for Alzheimer's disease: Data from the Swedish Dementia Registry, SveDem. https://app.cochat.ai/papers/10.1016/j.jalz.2015.04.007
- The paper
- Rosén, C., Farahmand, B., Skillbäck, T., Nägga, K., Mattsson, N., Kilander, L., Religa, D., Wimo, A., Blennow, K., Winblad, B., Zetterberg, H., & Eriksdotter, M. (2015). Benchmarking biomarker‐based criteria for Alzheimer's disease: Data from the Swedish Dementia Registry, SveDem. Alzheimer's & Dementia. https://doi.org/10.1016/j.jalz.2015.04.007
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.